Indivior Pharmaceuticals Inc.

INDV Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

32.45 1.17 −3.48%
Market cap
$4.0B
P/E
11.2×
Fwd P/E
11.8×
Dividend yield
0.00%
F-score
4/9
Altman Z
3.28
Beneish M
−1.52
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
725.00 667.00 652.00 922.00
Total non-current assets
507.00 530.00 550.00 496.00
Total Assets
1,233.00 1,197.00 1,201.00 1,416.00
Total current liabilities
868.00 779.00 914.00 965.00
Total non-current liabilities
573.00 562.00 385.00 658.00
Total liabilities
1,441.00 1,341.00 1,300.00 1,623.00
Common Equity (Total)
(207.00) (144.00) (99.00) (207.00)
Shareholders Equity (Total)
(208.00) (144.00) (98.00) (207.00)
Total Debt
487.00 486.00 319.00 322.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Oct 2026